Ignite Creation Date:
2024-05-06 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 2:19 PM
Study NCT ID:
NCT05153330
Status:
RECRUITING
Last Update Posted:
2024-05-17
First Post:
2021-11-30
Brief Title:
Study of BMF-219 a Covalent Menin Inhibitor in Adult Patients With AML ALL With KMT2A MLL1r NPM1 Mutations DLBCL MM and CLLSLL
Sponsor:
Biomea Fusion Inc
Organization:
Biomea Fusion Inc
Study Overview
Official Title:
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219 an Oral Covalent Menin Inhibitor in Adult Patients With Acute Leukemia AL Diffuse Large B-cell Lymphoma DLBCL Multiple Myeloma MM and Chronic Lymphocytic Leukemia CLL Small Lymphocytic Lymphoma SLL
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219 an oral covalent menin inhibitor in adult patients with AML ALL with KMT2A MLL1r NPM1 mutations DLBCL MM and CLLSLL
Detailed Description:
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219 an oral covalent menin inhibitor in adult patients with acute myeloid leukemia AML acute lymphocytic leukemia ALL with mixed lineage leukemia 1-rearranged KMT2A MLL1r nucleophosmin 1 NPM1 diffuse large b-cell lymphoma DLBCL multiple myeloma MM and chronic lymphocytic lymphoma CLL small lymphocytic lymphoma SLL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None